The Revolution of Robotic Stereotactic Radiotherapy (Robotic Radiosurgery) in Lung Cancer

Pierre-Yves Bondiau, MD, PhD (Editor)
Department of Radiation Oncology, Antoine-Lacassagne Cancer Center, Nice, France. University of Nice Sophia-Antipolis, Nice, France

Series: Cancer Etiology, Diagnosis and Treatments
BISAC: MED062000

Clear

$205.00

Volume 10

Issue 1

Volume 2

Volume 3

Special issue: Resilience in breaking the cycle of children’s environmental health disparities
Edited by I Leslie Rubin, Robert J Geller, Abby Mutic, Benjamin A Gitterman, Nathan Mutic, Wayne Garfinkel, Claire D Coles, Kurt Martinuzzi, and Joav Merrick

eBook

Digitally watermarked, DRM-free.
Immediate eBook download after purchase.

Product price
Additional options total:
Order total:

Quantity:

Details

Lung cancer, which was rare at the beginning of the 20th century, is now a major cause of cancer-related deaths in men and women. It is the most frequently diagnosed cancer in the world. With conventional radiation therapy, small doses of radiation are delivered on a daily Monday-to-Friday schedule over a period of approximately a month and a half. After receiving this therapy, some reversible side effects, such as local skin irritation, are common.

Robotic stereotactic radiotherapy is based on the principle of delivering high doses of radiation to the tumor while sparing or avoiding the surrounding tissues, which has been one of the greatest limiting factors of conventional radiation therapy historically. Given the advancements in technology, the reproducibility of patient positioning and the capability to deliver radiation from hundreds of different directions while synchronizing respiration-induced target motion, this technology is now proposed as a new local treatment, completed in less than one week, with promising results. (Imprint: Nova Biomedical )

Part I: Lung Cancer

Chapter 1 - Introduction to Stereotactic Body Radiotherapy (pp. 3-8)
Pierre-Yves Bondiau and Eric F. Lartigau (Department of Radiation Oncology, Antoine-Lacassagne Cancer Center, Nice, France and others)

Chapter 2 - History of Lung Cancer and Its Treatment (pp. 9-24)
Jérôme Mouroux (Department of Thoracic Surgery, Hôpital Pasteur, Centre Hospitalier Universitaire de Nice, and University of Nice Sophia-Antipolis, Nice, France)

Chapter 3 - Lung Cancer Classification (pp. 25-40)
Philippe Giraud (Université Paris Descartes, Service d’Oncologie Radiothérapie, Hôpital Européen Georges Pompidou, Paris, France)

Chapter 4 - Indication of CyberKnife in Lung Cancer (pp. 41-56)
Michel Poudenx and Pierre-Yves Bondiau (Department of Medical Oncology, Antoine-Lacassagne Cancer Center, Nice, and University of Nice Sophia-Antipolis, Nice, France)

Part IIa: Technique 55

Chapter 5 - Radiobiology and Its Applications to Stereotactic Body Radiotherapy (pp. 57-76)
Adel Courdi (Department of Radiation Oncology, Antoine-Lacassagne Cancer Center, Nice, France)

Chapter 6 - CyberKnife Description (pp. 77-90)
Serge Marcié, Karen Bénézery and Pierre-Yves Bondiau (Department of Radiation Oncology, Antoine-Lacassagne Cancer Center, Nice, and University of Nice Sophia-Antipolis, Nice, France)

Part IIb: Tracking

Chapter 7 - CyberKnife Tracking Methods (pp. 93-100)
Pierre-Yves Bondiau (Department of Radiation Oncology, Antoine-Lacassagne Cancer Center, Nice, and University of Nice Sophia-Antipolis, Nice, France)

Chapter 8 - Role of Bronchoscopy in Implantation of Fiducial Markers for CyberKnife Treatment of Pulmonary Tumors (pp. 101-116)
S. Marco, Pierre-Yves Bondiau, C. H. Marquette and M. Poudenx (Department of Pneumology, Thoracic Oncology and Respiratory Intensive Care, Hôpital Pasteur, Centre Hospitalier Universitaire de Nice, France and others)

Chapter 9 - Image-Guided Stereotactic Body Radiation Therapy with Fiducial-Free Tumor Tracking for Lung Cancer (pp. 117-130)
Jean-Emmanuel Bibault, Bernard Prevost, Eric Dansin, Xavier Mirabel, Thomas Lacornerie and Eric F. Lartigau (Department of Radiation Oncology, Oscar Lambret Cancer Center, University Lille II and ONCOLille Consortium, Lille, France)

Part III: CyberKnife Treatment

Chapter 10 - CyberKnife with Fiducial Tracking for Inoperable Peripheral Stage I Non-Small Cell Lung Cancer (NSCLC): Locoregional Control and Overall Survival Outcomes (pp. 133-142)
Brian T. Collins, Eric K. Oermann, Shaan Kataria, Catherine Jamis, Saloomeh Vahdat, Leonard Chen, Simeng Suy, Sean P. Collins and Eric Anderson (Georgetown University Hospital, Washington, DC, US)

Chapter 11 - Central Lung Tumors (pp. 143-148)
Joost Jan Nuyttens (Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, the Netherlands)

Chapter 12 - CyberKnife Treatment for Stage III Lung Tumors (pp. 149-156)
Pierre-Yves Bondiau (Department of Radiation Oncology, Antoine-Lacassagne Cancer Center, Nice, France)

Chapter 13 - Stereotactic Ablative Re-Irradiation in Relapsed Non–Small Cell Lung Cancer (pp. 157-170)
Jérôme Doyen and Pierre-Yves Bondiau (Department of Radiation Oncology, Antoine-Lacassagne Cancer Center, Nice, and University of Nice Sophia-Antipolis, Nice, France)

Chapter 14 - Treatment of Lung Metastasis (pp. 171-176)
Joost Jan Nuyttens, Juliette Van Loon and Pierre-Yves Bondiau (Department of Radiation Oncology, Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, the Netherlands and others)

Chapter 15 - Toxicity Outcomes in Studies of the Stereotactic Radiotherapy of Lung Tumors (pp. 177-202)
Axel Leysalle and Pierre-Yves Bondiau (Department of Radiation Oncology, Antoine-Lacassagne Cancer Center, Nice, and University of Nice Sophia-Antipolis, Nice, France)

Chapter 16 - Other Local Treatments (pp. 203-208)
Pierre-Yves Bondiau (Department of Radiation Oncology, Antoine-Lacassagne Cancer Center, Nice, France)

Part IV: Conclusion

Conclusion
Pierre-Yves Bondiau

Part V: Annexes

Annex A: List of Abbreviations

Annex B: Margins for Cyberknife Treatment

Annex C: Organ at Risk Constraint

Annex D: Patient Positioning

Annex E: Dosimetric CT Scan Characteristics

Annex F: Dosimetric PET/CT System Characteristics

Editor’s Contact Information

Index

You have not viewed any product yet.